drugset / Trial / NCT07617285
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Phase 1
Recruiting
27 enrolled
Peking University People's Hospital
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Timeline
- Start
- 2026-05-07
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT0890B | Cell therapy | 1.5e+08 cells | — |
| Subject | CT0890B | Cell therapy | 3e+08 cells | — |
| Subject | CT0890B | Cell therapy | 4.5e+08 cells | — |
| Subject | CT0890B | Cell therapy | 6e+08 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Cytarabine | Small molecule | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Venetoclax | Small molecule | 200 mg | — |